Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 9/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | CA12 | O43570 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resokaempferol SCHEMBL4728192 | 0.91 | MEN1 (0.82) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL31675772 | 0.88 | MEN1 (0.81) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL1628821 | 0.88 | DHFR (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL344155 | 0.88 | MEN1 (0.81) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL27595696 | 0.88 | KDM4E (0.90) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL20246 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL1679068 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL29433939 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL15676318 | 0.85 | KDM4E (0.74) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL30807185 | 0.85 | KDM4E (0.74) | MEN1KMT2AKDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249431-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-08-11 | — | — | US | claimed |
| EP-4003522-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | claimed |
| WO-2021013931-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2021-01-28 | — | — | WO | claimed |
| EP-3769815-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2021-01-27 | — | — | EP | claimed |
| US-7897637-B2 | Methods of using flavonoids to enhance memory | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-03-01 | — | — | US | claimed |
| WO-2008011538-A2 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-01-24 | — | — | WO | claimed |
| US-20080021096-A1 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2008-01-24 | — | — | US | claimed |
| WO-2006030322-A2 | USE OF FLA VONE/FLA VANONE DERIVATIVES FN THE TREATMENT OR PREVENTION OF RESPIRATORY CONDITIONS | UNIVERSITY OF MANITOBA (CA) | 2006-03-23 | — | — | WO | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001080855-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| US-20250263774-A1 | DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD | UNIV NORTH TEXAS (US) | 2025-08-21 | — | — | US | disclosed |
| US-20220249431-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-08-11 | — | — | US | disclosed |
| EP-4003522-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021096-A1 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | FOS, CREBBP, CREB1 | MEN1 3520/4885KMT2A 1152/4885KDM4E 338/4885 |
| US-20220249431-A1 | ANTIMYCOTIC | ETF1, FOXM1, RIF1 | MEN1 1320/4885KMT2A 3803/4885KDM4E 1705/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | MEN1 3867/4885KMT2A 4306/4885KDM4E 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.